ANKYLOSING SPONDYLITIS AND HL-A 27

doi:10.1016/S0140-6736(73)91360-3

The Lancet

Volume 301, Issue 7809, 28 April 1973, Pages 904-907

https://doi.org/10.1016/S0140-6736(73)91360-3 Get rights and content

Abstract

Using a standard microcytotoxicity technique of tissue typing, the HL-A 27 antigen was identified in 72 out of 75 patients with classical ankylosing spondylitis and in 3 out of 75 controls. The same antigen was found in 31 out of 60 first-degree relatives.

References (38)

J.D. Zervas et al.
Lancet
(1970)
J. Falk et al.
Lancet
(1971)
P.L. Stokes et al.
Lancet
(1972)
H.O. McDevitt et al.
Am. J. Med.
(1972)
F. Kueppers et al.
Lancet
(1972)
M.Q. Birkbeck et al.
Lancet
(1951)
I. Aird et al.
Br. med. J.
(1953)
J.H. Renwick et al.
Ann. hum Genet.
(1955)
A.M.G. Kornstad et al.
Ann. rheum. Dis.
(1968)
J.L. Amiel
Histocompatibility Testing, 1967
(1967)

J.F. Forbes et al.

Lancet

(1970)

J. Bertrams et al.

Tissue Antigens

(1972)

R.L. Walford et al.

Transplant. Rev.

(1971)

F.C. Grumet et al.

New Engl. J. Med.

(1971)

S.D. Lawler et al.

Br. J. Hœmat.

(1971)

T.J. Russell et al.

New Engl. J. Med.

(1972)

J. Seignalet et al.

Vox Sang.

(1972)

R.B. Lies et al.

Arthritis Rheum.

(1972)

Cited by (1518)

Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital
2024, Rheumatic Disease Clinics of North America
PRICKLE1 gene methylation and abnormal transcription in Chinese patients with ankylosing spondylitis
2023, Immunobiology
Ankylosing spondylitis (AS) is a common inflammatory arthritis without a reliable biomarker. The role of methylation and mRNA expression of PRICKLE1 promoter in the pathogenesis of ankylosing spondylitis remains unclear.
A two-stage case-control design was used to detect the characteristics of methyl group and transcriptome of PRICKLE1 gene in Ankylosing spondylitis. The methylation degree of PRICKLE1 gene promoter region was tested by phosphate-sequencing, and further analyzed whether there was significant difference in methylation level of PRICKLE1 gene. The expression levels of PRICKLE1 mRNA in 50 AS patients and 50 healthy controls were detected by real-time quantitative PCR (RT-qPCR).
Compared with healthy control group, the intensity of methylation in 4 ponds of PRICKLE1 in patients with Ankylosing spondylitis was low, and the mRNA levels were overexpressed (P = 0.017). ROC results showed that the sensitivity of PRICKLE1 was 68.67% and specificity was 71.43%.
There is a significant change in the concentration of serum PRICKLE1 mRNAin patients with Ankylosing spondylitis, and the degree of gene methylation is significantly reduced, suggesting that PRICKLE1 gene maybe involved in the pathogenesis of Ankylosing spondylitis, which may be useful for predicting the occurrence of AS and finding new early screening indicators.
Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility
2023, American Journal of Human Genetics
Autoimmunity and cancer represent two different aspects of immune dysfunction. Autoimmunity is characterized by breakdowns in immune self-tolerance, while impaired immune surveillance can allow for tumorigenesis. The class I major histocompatibility complex (MHC-I), which displays derivatives of the cellular peptidome for immune surveillance by CD8⁺ T cells, serves as a common genetic link between these conditions. As melanoma-specific CD8⁺ T cells have been shown to target melanocyte-specific peptide antigens more often than melanoma-specific antigens, we investigated whether vitiligo- and psoriasis-predisposing MHC-I alleles conferred a melanoma-protective effect. In individuals with cutaneous melanoma from both The Cancer Genome Atlas (n = 451) and an independent validation set (n = 586), MHC-I autoimmune-allele carrier status was significantly associated with a later age of melanoma diagnosis. Furthermore, MHC-I autoimmune-allele carriers were significantly associated with decreased risk of developing melanoma in the Million Veteran Program (OR = 0.962, p = 0.024). Existing melanoma polygenic risk scores (PRSs) did not predict autoimmune-allele carrier status, suggesting these alleles provide orthogonal risk-relevant information. Mechanisms of autoimmune protection were neither associated with improved melanoma-driver mutation association nor improved gene-level conserved antigen presentation relative to common alleles. However, autoimmune alleles showed higher affinity relative to common alleles for particular windows of melanocyte-conserved antigens and loss of heterozygosity of autoimmune alleles caused the greatest reduction in presentation for several conserved antigens across individuals with loss of HLA alleles. Overall, this study presents evidence that MHC-I autoimmune-risk alleles modulate melanoma risk unaccounted for by current PRSs.
Sequence of Events in the Pathogenesis of Axial Spondyloarthritis: A Current Review—2023 SPARTAN Meeting Proceedings
2024, Current Rheumatology Reports
The role of HLA-B27 in the pathogenesis and diagnosis of axial spondyloarthritis: 50 years after discovery of the strong genetic association
2024, Zeitschrift fur Rheumatologie
Patients with ankylosing spondylitis present a distinct CD8 T cell subset with osteogenic and cytotoxic potential
2024, RMD Open

View all citing articles on Scopus

View full text

ANKYLOSING SPONDYLITIS AND HL-A 27

Abstract

Lancet

Lancet

Lancet

Am. J. Med.

Lancet

Lancet

Br. med. J.

Ann. hum Genet.

Ann. rheum. Dis.

Histocompatibility Testing, 1967

Lancet

Tissue Antigens

Transplant. Rev.

New Engl. J. Med.

Br. J. Hœmat.

New Engl. J. Med.

Vox Sang.

Arthritis Rheum.